The workflow of radiomics. Image courtesy of Yixin Wang

The workflow of radiomics. Image courtesy of Yixin Wang 


June 24, 2022 — Recently, a collaborated research team led by Prof. LI Hai and Hongzhi Wang from Hefei Institutes of Physical Science of Chinese Academy of Sciences (CAS) proposed an interpretable radiomic model for predicting radiotherapy treatment response in patients with brain metastases

The results were published in European Radiology

Radiomics refers to extracting high-throughput radiomic features from medical images to assist clinical decision-making. These radiomic features can reflect the biological information of tumors, which cannot be obtained directly through conventional image interpretation. Therefore, machine learning-based methods can rely on in-depth data mining to obtain additional knowledge about tumor heterogeneity. Currently, there is no accurate prediction model of radiotherapy treatment response for patients with brain metastases in clinical practice. 

In this research, the team proposed an interpretable radiomic model for predicting radiotherapy treatment response in patients with brain metastases by combining radiomics and SHAP methods to solve this clinical problem. 

Yixin Wang, the first author of the paper, explained how they finished the whole process. At first, the research team extracted the radiomic features from the magnetic resonance imaging (MRI) images of patients with brain metastases before radiotherapy. Then they used the machine learning method to build the radiomic model. In the end, they explained the model using the game theory-based SHAP, which is helpful for the formulation of precise radiotherapy for patients with brain metastases. 

The model had good performance, and the prediction results in the external validation group also showed that the model can be generalizability. At the same time, the SHAP method could realize the interpretability and visualization of the model and avoid the "black box" effect of traditional machine learning algorithms, which was beneficial for clinicians to understand the model and promote the use of the model. 

This work was supported by the Key Research and Development Program of Anhui Province, the Collaborative Innovation Cultivation Fund of Hefei, Big Science Center of CAS, and the Key Clinical Cultivation Specialty of Hefei Cancer Hospital of CAS. 

For more information: https://english.hf.cas.cn/ 

Related Brain Metastases Content: 

PET Imaging Adds Valuable Information to Brain Metastasis Monitoring 

Blue Earth Diagnostics Announces Dosing of Initial Patient in Phase 3 REVELATE Clinical Trial of 18F-Fluciclovine PET Imaging for Detection of Recurrent Brain Metastases 

Radiosurgery Reduces Cognitive Decline Without Compromising Survival for Patients with 4+ Brain Metastases 

ASTRO Issues Clinical Guideline on Radiation Therapy for Brain Metastases 


Related Content

News | Radiation Therapy

Feb. 4, 2026 — On World Cancer Day (02.04.26), the American Society for Radiation Oncology (ASTRO) and the European ...

Time February 04, 2026
arrow
News | Radiology Imaging

Feb. 4, 2026 — The Royal College of Radiologists (RCR) has issued its initial reaction to the British government's ...

Time February 04, 2026
arrow
News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
Subscribe Now